Reference : Host interleukin 6 production regulates inflammation but not tryptophan metabolism in...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/218849
Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD
English
Belle, Ludovic mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Zhou, Vivian []
Stuhr, KL []
Beatka, Margaret []
Siebers, Emilie []
Knight, J []
Lawlor, M []
Weaver, C []
Hashizume, M []
Hillard, Cecilia []
Drobyski, William R []
20-Jul-2017
JCI Insight
2
14
Yes
International
2379-3708
[en] Graft-versus-Host Disease ; Central Nervous System ; Interleukin-6
[en] Graft-versus-host disease (GVHD) induces pathological damage in peripheral target organs leading to well-characterized, organ-specific clinical manifestations. Patients with GVHD, however, can also have behavioral alterations that affect overall cognitive function, but the extent to which GVHD alters inflammatory and biochemical pathways in the brain remain poorly understood. In the current study, we employed complementary murine GVHD models to demonstrate that alloreactive donor T cells accumulate in the brain and affect a proinflammatory cytokine milieu that is associated with specific behavioral abnormalities. Host IL-6 was identified as a pivotal cytokine mediator, as was host indoleamine 2,3-dioxygenase (IDO-1), which was upregulated in GVHD in an IL-6-dependent manner in microglial cells and was accompanied by dysregulated tryptophan metabolism in the dorsal raphe nucleus and prefrontal cortex. Blockade of the IL-6 signaling pathway significantly reduced donor T cell accumulation, inflammatory cytokine gene expression, and host microglial cell expansion, but did not reverse GVHD-induced tryptophan metabolite dysregulation. Thus, these results indicate that inhibition of IL-6 signaling attenuates neuroinflammation, but does not reverse all of the metabolic abnormalities in the brain during GVHD, which may also have implications for the treatment of neurotoxicity occurring after other T cell-based immune therapies with IL-6-directed approaches.
Researchers ; Professionals
http://hdl.handle.net/2268/218849
10.1172/jci.insight.93726
https://www.ncbi.nlm.nih.gov/pubmed/28724796

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2017_Belle_aGvHD&CNS.pdfPublisher postprint1.86 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.